{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T19:21:22Z","timestamp":1778095282190,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12325-025-03112-y","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:16:46Z","timestamp":1739146606000},"page":"1550-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-4172","authenticated-orcid":false,"given":"Florian","family":"Zeevat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjalke","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"11","key":"3112_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1152\/physiolgenomics.00089.2020","volume":"52","author":"CA Pollard","year":"2020","unstructured":"Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genom. 2020;52(11):549\u201357. https:\/\/doi.org\/10.1152\/physiolgenomics.00089.2020.","journal-title":"Physiol Genom"},{"key":"3112_CR2","doi-asserted-by":"publisher","unstructured":"Network TWERS. Estimated number of lives directly saved by COVID-19 vaccination programs in the WHO European Region, December 2020 to March 2023. 2024:2024.01.12.24301206. https:\/\/doi.org\/10.1101\/2024.01.12.24301206.","DOI":"10.1101\/2024.01.12.24301206"},{"key":"3112_CR3","unstructured":"Current information about COVID-19 | RIVM. https:\/\/www.rivm.nl\/en\/coronavirus-covid-19\/current. Accessed 21 Feb 2024."},{"key":"3112_CR4","unstructured":"Ministerie van Volksgezondheid W en S. Vervolgadvies tweede boostervaccinatie tegen COVID-19 - Advies - Gezondheidsraad. 2022. https:\/\/www.gezondheidsraad.nl\/documenten\/adviezen\/2022\/03\/25\/vervolgadvies-tweede-boostervaccinatie-tegen-covid-19. Accessed 21 Feb 2024."},{"key":"3112_CR5","unstructured":"Bivalente covidboosters beschermen tegen omikron | NTvG. 2022. https:\/\/www.ntvg.nl\/artikelen\/bivalente-covidboosters-beschermen-tegen-omikron. Accessed 22 Nov 2023."},{"key":"3112_CR6","unstructured":"Ministerie van Volksgezondheid W en S. Kamerbrief over COVID-19-vaccinaties voor specifieke doelgroepen in het najaar van 2023 - Kamerstuk - Rijksoverheid.nl. 2023. https:\/\/www.rijksoverheid.nl\/documenten\/kamerstukken\/2023\/09\/13\/kamerbrief-over-uitvoering-covid-19-vaccinatieronde-voor-specifieke-doelgroepen-in-het-najaar-van-2023. Accessed 21 Feb 2024."},{"key":"3112_CR7","unstructured":"Ministerie van Volksgezondheid W en S. Structureel vaccinatieprogramma tegen COVID-19 - Vaccinaties - Gezondheidsraad. 2023. https:\/\/www.gezondheidsraad.nl\/onderwerpen\/vaccinaties\/alle-adviezen-over-covid-19-vaccinaties\/structureel-vaccinatieprogramma-tegen-covid-19. Accessed 21 Feb 2024."},{"key":"3112_CR8","unstructured":"Zaken M van A. Coronaprik - Vaccinatie tegen het coronavirus - Rijksoverheid.nl. 2020. https:\/\/www.rijksoverheid.nl\/onderwerpen\/coronavirus-vaccinatie\/aanpak-coronavaccinatie. Accessed 22 Nov 2023."},{"key":"3112_CR9","unstructured":"COVID-19-vaccinatie | LCI richtlijnen. https:\/\/lci.rivm.nl\/richtlijnen\/covid-19-vaccinatie. Accessed 22 Nov 2023."},{"key":"3112_CR10","doi-asserted-by":"publisher","unstructured":"Kavikondala S, Haeussler K, Wang X, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: systematic literature review and meta-analysis using the GRADE framework. 2023:2023.11.21.23298832. https:\/\/doi.org\/10.1101\/2023.11.21.23298832.","DOI":"10.1101\/2023.11.21.23298832"},{"key":"3112_CR11","doi-asserted-by":"publisher","unstructured":"Lee A, Jayasundara K, Kohli M, et al. Clinical and economic impact of updated fall 2023 COVID-19 vaccines in the immunocompromised population in Canada. 2023:2023.11.10.23298369. https:\/\/doi.org\/10.1101\/2023.11.10.23298369.","DOI":"10.1101\/2023.11.10.23298369"},{"key":"3112_CR12","unstructured":"Ministerie van Volksgezondheid W en S. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg - Publicatie - Zorginstituut Nederland. 2016. https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg.pdf. Accessed 20 June 2023."},{"key":"3112_CR13","unstructured":"StatLine - Prognose bevolking; geslacht en leeftijd, 2023\u20132070. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/85324NED\/table?ts=1686053339042. Accessed 22 Nov 2023."},{"key":"3112_CR14","unstructured":"Heins M, Korevaar J, Knottnerus B, Hooiveld M. Monitor Vaccinatiegraad Nationaal Programma Grieppreventie (NPG) 202. Published online 2021."},{"key":"3112_CR15","unstructured":"Deelname COVID-19-vaccinatie in Nederland (16 januari 2024) | RIVM. https:\/\/www.rivm.nl\/documenten\/deelname-covid-19-vaccinatie-in-nederland-16-januari-2024. Accessed 27 Feb 2024."},{"issue":"5","key":"3112_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","volume":"11","author":"N Wu","year":"2023","unstructured":"Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11(5):439\u201352. https:\/\/doi.org\/10.1016\/S2213-2600(23)00015-2.","journal-title":"Lancet Respir Med"},{"key":"3112_CR17","unstructured":"Driekwart minder kans op ziekenhuisopname na corona-herhaalprik | RIVM. https:\/\/www.rivm.nl\/nieuws\/driekwart-minder-kans-op-ziekenhuisopname-na-corona-herhaalprik. Accessed 6 Mar 2024."},{"key":"3112_CR18","unstructured":"COVID-19 dataset. https:\/\/data.rivm.nl\/covid-19\/. Accessed 20 July 2023."},{"key":"3112_CR19","unstructured":"RIVM. COVID-19 ziekenhuis en intensive-care-opnames per vaccinatiestatus in Nederland (opnames 3 oktober 2022 \u2013 29 mei 2023). 2023. https:\/\/www.rivm.nl\/documenten\/covid-19-ziekenhuis-en-intensive-care-opnames-per-vaccinatiestatus-in-nederland-10. Accessed 4 Aug 2023."},{"key":"3112_CR20","unstructured":"Centraal Bureau voor de Statistiek. Bevolking op 1 januari en gemiddeld; geslacht, leeftijd en regio. Centraal Bureau voor de Statistiek. 2022. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/03759ned?dl=39E0B. Accessed 4 Apr 2023."},{"issue":"8","key":"3112_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13174","volume":"17","author":"PT de Boer","year":"2023","unstructured":"de Boer PT, van de Kassteele J, Vos ERA, et al. Age-specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands. Influenza Other Respir Viruses. 2023;17(8):e13174. https:\/\/doi.org\/10.1111\/irv.13174.","journal-title":"Influenza Other Respir Viruses"},{"issue":"12","key":"3112_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S1473-3099(21)00685-X","volume":"21","author":"E Bast","year":"2021","unstructured":"Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the USA. Lancet Infect Dis. 2021;21(12):1629\u201330. https:\/\/doi.org\/10.1016\/S1473-3099(21)00685-X.","journal-title":"Lancet Infect Dis"},{"key":"3112_CR23","doi-asserted-by":"publisher","unstructured":"Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(22)00462-7.","DOI":"10.1016\/S0140-6736(22)00462-7"},{"key":"3112_CR24","unstructured":"NICE. Covid-19 infecties op de IC. https:\/\/www.stichting-nice.nl\/covid-19-op-de-ic.jsp. Accessed 22 Nov 2023."},{"key":"3112_CR25","unstructured":"Sterfte en heropname na ziekenhuisopname met covid-19 | NTvG. 2020. https:\/\/www.ntvg.nl\/artikelen\/sterfte-en-heropname-na-ziekenhuisopname-met-covid-19. Accessed 22 Nov 2023."},{"key":"3112_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajem.2021.10.059","volume":"51","author":"ZS Ramzi","year":"2022","unstructured":"Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; a systematic review and meta-analysis. Am J Emerg Med. 2022;51:267\u201379. https:\/\/doi.org\/10.1016\/j.ajem.2021.10.059.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"3112_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2020.11.002","volume":"24","author":"F Zeevat","year":"2021","unstructured":"Zeevat F, Cr\u00e9pey P, Dolk FCK, Postma AJ, Breeveld-Dwarkasing VNA, Postma MJ. Cost-effectiveness of quadrivalent versus trivalent influenza vaccination in the Dutch National Influenza Prevention Program. Value Health. 2021;24(1):3\u201310. https:\/\/doi.org\/10.1016\/j.jval.2020.11.002.","journal-title":"Value Health"},{"key":"3112_CR28","unstructured":"Economic analysis of vaccination with mRNA booster dose against COVID-19 among adults. https:\/\/stacks.cdc.gov\/view\/cdc\/132890. Accessed 6 Mar 2024."},{"key":"3112_CR29","unstructured":"\u00c4rzteblatt D\u00c4G Redaktion Deutsches. Angepasster Moderna-Impfstoff ab 1. Oktober bestellbar. Deutsches \u00c4rzteblatt. 2023. https:\/\/www.aerzteblatt.de\/nachrichten\/146254\/Angepasster-Moderna-Impfstoff-ab-1-Oktober-bestellbar. Accessed 6 Mar 2024."},{"key":"3112_CR30","unstructured":"Polder J, van Exel, Kahlman J, et al. Kennisplatform: Preventie op waarde schatten. ZonMW. 2023. https:\/\/www.zonmw.nl\/nl\/nieuws\/kennisplatform-preventie-op-waarde-schatten. Accessed 6 Mar 2024."},{"issue":"28","key":"3112_CR31","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.vaccine.2015.05.001","volume":"33","author":"MH Rozenbaum","year":"2015","unstructured":"Rozenbaum MH, Mangen MJJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine. 2015;33(28):3193\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.001.","journal-title":"Vaccine"},{"key":"3112_CR32","unstructured":"Veel mensen die ziek zijn door post-covid gaan gewoon naar hun werk. Vooral vrouwen en hoogopgeleiden. Zo zit dat. Dagblad van het Noorden. 2023. https:\/\/dvhn.nl\/meer\/gezond\/Een-op-vijf-pati%C3%ABnten-werkt-door-met-post-covid-blijkt-uit-Gronings-onderzoek.-Gezond-is-dat-niet.-Vooral-vrouwen-en-hogeropgeleiden-werken-met-klachten.-Hoe-kan-dat-28358318.html. Accessed 29 Nov 2023."},{"key":"3112_CR33","unstructured":"StatLine - Werkzame beroepsbevolking; arbeidsduur, 2003\u20132022. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/82647NED\/table. Accessed 22 Nov 2023."},{"issue":"6","key":"3112_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/M18-2347","volume":"170","author":"LA Prosser","year":"2019","unstructured":"Prosser LA, Harpaz R, Rose AM, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380\u20138. https:\/\/doi.org\/10.7326\/M18-2347.","journal-title":"Ann Intern Med"},{"key":"3112_CR35","unstructured":"Nederland Z. TRAMADOL HCL\/PARACETAM AUR TAB FILMOMH 37,5\/325MG | Medicijnkosten.nl. https:\/\/www.medicijnkosten.nl\/medicijn?artikel=TRAMADOL+HCL%2FPARACETAM+AUR+TAB+FILMOMH+37%2C5%2F325MG&id=07d21c743d7c5877b89d9ef18330e005. . Accessed 22 Nov 2023."},{"issue":"6","key":"3112_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004245","volume":"20","author":"J Stowe","year":"2023","unstructured":"Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: a self-controlled case series analysis in England. PLoS Med. 2023;20(6):e1004245. https:\/\/doi.org\/10.1371\/journal.pmed.1004245.","journal-title":"PLoS Med"},{"key":"3112_CR37","unstructured":"StatLine - Ziekenhuisopnamen en -pati\u00ebnten; diagnose-indeling ICD-10 (3-teken niveau). https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/84069NED\/table. Accessed 27 Nov 2023."},{"key":"3112_CR38","unstructured":"Ministerie van Volksgezondheid W en S. Nota 15\u00a0minuten observatieperiode na COVID-19-vaccinatie\u2014Rapport\u2014Rijksoverheid.nl. 2023. https:\/\/www.rijksoverheid.nl\/documenten\/rapporten\/2023\/07\/05\/nota-15-minuten-observatieperiode-na-covid-19-vaccinatie. Accessed 6 Mar 2024."},{"issue":"2","key":"3112_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/vaccines9020111","volume":"9","author":"T Fens","year":"2021","unstructured":"Fens T, de Boer PT, van Puijenbroek EP, Postma MJ. Inclusion of safety-related issues in economic evaluations for seasonal influenza vaccines: a systematic review. Vaccines (Basel). 2021;9(2):111. https:\/\/doi.org\/10.3390\/vaccines9020111.","journal-title":"Vaccines (Basel)"},{"key":"3112_CR40","unstructured":"Vergoeding. SNPG. https:\/\/www.snpg.nl\/article\/griep-ha-afronden\/declareren-griepvaccinaties\/vergoeding\/. Accessed 22 Nov 2023."},{"key":"3112_CR41","doi-asserted-by":"publisher","unstructured":"Postma MJ, Jansema P, Scheijbeler HWKFH, van Genugten MLL. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine. 2005;23(46\u201347):5365\u201371. https:\/\/doi.org\/10.1016\/j.vaccine.2005.06.007.","DOI":"10.1016\/j.vaccine.2005.06.007"},{"key":"3112_CR42","doi-asserted-by":"publisher","unstructured":"Bekker R, uit het Broek M, Koole G. Modeling COVID-19\u00a0hospital admissions and occupancy in the Netherlands. Eur J Oper Res. 2023;304(1):207\u201318. https:\/\/doi.org\/10.1016\/j.ejor.2021.12.044.","DOI":"10.1016\/j.ejor.2021.12.044"},{"key":"3112_CR43","doi-asserted-by":"publisher","DOI":"10.7326\/M20-5661","author":"V Chopra","year":"2020","unstructured":"Chopra V, Flanders SA, O\u2019Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-5661.","journal-title":"Ann Intern Med"},{"key":"3112_CR44","unstructured":"van Zon S. Presented at ACTION conference; April 2023."},{"issue":"1","key":"3112_CR45","doi-asserted-by":"publisher","first-page":"e962","DOI":"10.1093\/cid\/ciac151","volume":"75","author":"FG Sandmann","year":"2022","unstructured":"Sandmann FG, Tessier E, Lacy J, et al. Long-term health-related quality of life in non-hospitalized coronavirus disease 2019 (COVID-19) cases with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England: longitudinal analysis and cross-sectional comparison with controls. Clin Infect Dis. 2022;75(1):e962\u201373. https:\/\/doi.org\/10.1093\/cid\/ciac151.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3112_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2213-2600(22)00127-8","volume":"10","author":"PHOSP-COVID Collaborative Group","year":"2022","unstructured":"PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761\u201375. https:\/\/doi.org\/10.1016\/S2213-2600(22)00127-8.","journal-title":"Lancet Respir Med"},{"issue":"35","key":"3112_CR47","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.15585\/mmwr.mm7035e5","volume":"70","author":"TK Boehmer","year":"2021","unstructured":"Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data\u2014United States, March 2020\u2013January 2021. Morb Mortal Wkly Rep. 2021;70(35):1228. https:\/\/doi.org\/10.15585\/mmwr.mm7035e5.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"1","key":"3112_CR48","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1080\/13696998.2023.2281083","volume":"26","author":"MA Kohli","year":"2023","unstructured":"Kohli MA, Maschio M, Joshi K, et al. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. J Med Econ. 2023;26(1):1532\u201345. https:\/\/doi.org\/10.1080\/13696998.2023.2281083.","journal-title":"J Med Econ"},{"key":"3112_CR49","unstructured":"Shimabukuro T. Covid-19 vaccine safety update: primary series in young childre and booster doses in older children and adults. Advisory Committee on Immunization Practices (ACIP). 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2022-09-01\/05-COVID-Shimabukuro-508.pdf."},{"issue":"6","key":"3112_CR50","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cjca.2022.12.003","volume":"39","author":"M Zuin","year":"2023","unstructured":"Zuin M, Rigatelli G, Bilato C, et al. One-year risk of myocarditis after COVID-19 infection: a systematic review and meta-analysis. Can J Cardiol. 2023;39(6):839\u201344. https:\/\/doi.org\/10.1016\/j.cjca.2022.12.003.","journal-title":"Can J Cardiol"},{"issue":"1","key":"3112_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","volume":"41","author":"C Willame","year":"2023","unstructured":"Willame C, Dodd C, Dur\u00e1n C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases\u2014an ACCESS cohort study. Vaccine. 2023;41(1):251\u201362. https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.031.","journal-title":"Vaccine"},{"key":"3112_CR52","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0098-2022","author":"CI Vardavas","year":"2022","unstructured":"Vardavas CI, Mathioudakis AG, Nikitara K, et al. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. Eur Respir Rev. 2022. https:\/\/doi.org\/10.1183\/16000617.0098-2022.","journal-title":"Eur Respir Rev"},{"issue":"32","key":"3112_CR53","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1016\/j.vaccine.2022.05.048","volume":"40","author":"N Abraham","year":"2022","unstructured":"Abraham N, Spruin S, Rossi T, et al. Myocarditis and\/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 2022;40(32):4663\u201371. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.048.","journal-title":"Vaccine"},{"issue":"6","key":"3112_CR54","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","volume":"7","author":"\u00d8 Karlstad","year":"2022","unstructured":"Karlstad \u00d8, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a nordic cohort study of 23\u00a0million residents. JAMA Cardiol. 2022;7(6):600\u201312. https:\/\/doi.org\/10.1001\/jamacardio.2022.0583.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"3112_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18505","volume":"5","author":"SA Buchan","year":"2022","unstructured":"Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open. 2022;5(6):e2218505. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.18505.","journal-title":"JAMA Netw Open"},{"key":"3112_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae056","author":"A Hviid","year":"2024","unstructured":"Hviid A, Nieminen TA, Pihlstr\u00f6m N, et al. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae056.","journal-title":"Eur Heart J"},{"key":"3112_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.951314","author":"N Voleti","year":"2022","unstructured":"Voleti N, Reddy SP, Ssentongo P. Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis. Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.951314.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3112_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13696998.2023.2290388","volume":"27","author":"K Joshi","year":"2024","unstructured":"Joshi K, Scholz S, Maschio M, et al. Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. J Med Econ. 2024;27(1):39\u201350. https:\/\/doi.org\/10.1080\/13696998.2023.2290388.","journal-title":"J Med Econ"},{"key":"3112_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"16","key":"3112_CR60","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jama.2024.16380","volume":"332","author":"L Semenzato","year":"2024","unstructured":"Semenzato L, Le Vu S, Botton J, et al. Long-term prognosis of patients with myocarditis attributed to COVID-19 mRNA vaccination, SARS-CoV-2 infection, or conventional etiologies. JAMA. 2024;332(16):1367\u201377. https:\/\/doi.org\/10.1001\/jama.2024.16380.","journal-title":"JAMA"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03112-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:38:25Z","timestamp":1740627505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03112-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3112"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03112-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.26.24314420","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maarten J. Postma and Cornelis Boersma received grants and honoraria from various pharmaceutical companies, inclusive those developing, producing and marketing vaccines. Tjalke Westra and Ekkehard Beck are an employee and shareholder of Moderna, Inc. Florian Zeevat, and Simon van der Pol have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}